Market Size of Rapid Plasma Reagin Test Industry
Study Period | 2019 - 2029 |
Base Year For Estimation | 2023 |
Forecast Data Period | 2024 - 2029 |
CAGR | 4.10 % |
Fastest Growing Market | Asia Pacific |
Largest Market | North America |
Major Players*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Rapid Plasma Reagin Test Market Analysis
The market for the rapid plasma reagin test is expected to exhibit a CAGR of 4.1% during the forecast period.
- The COVID-19 pandemic had a significant impact on market growth, as syphilis diagnoses decreased during the early stages of the pandemic. However, there was an increase in syphilis infections during the post-pandemic market scenario, which drove the demand for the rapid plasma reagin test. This rise in syphilis is expected to contribute to the growth of the market during the post-pandemic period.
- The rapid plasma reagin (RPR) test is a serological test used to screen for syphilis, a sexually transmitted infection caused by the spirochete bacterium Treponema pallidum. The market for the rapid plasma reagin test is being driven by an increasing prevalence of syphilis and increased awareness of sexually transmitted diseases.
- According to a report published by the World Health Organization (WHO) in July 2021, the global pooled prevalence of syphilis among homosexuals was 7.5%, and globally, there were an estimated 7 million new syphilis infections in 2021. The high rate of syphilis prevalence is expected to drive the demand for rapid plasma reagin tests, thereby contributing to the growth of the market. Additionally, the prevalence of syphilis infections among pregnant women is expected to drive the growth of the market owing to the growing demand for early diagnosis to obtain proper treatment.
- Several initiatives are being taken regarding STD diagnostics, further supporting the growth of the market over the forecast period. For instance, in December 2021, Clinton Health Access Initiative (CHAI), MedAccess, and SD Biosensor partnered to develop dual Syphilis rapid diagnostics tests for a cost under USD 1, which is recommended by the WHO. Such initiatives are augmenting the demand for rapid tests for the rapid plasma reagin test, which is expected to contribute to the growth of the market over the forecast period. However, the lack of adoption of disease screening in developing countries is expected to restrain the growth of the market over the forecast period.